Arbutus files patent lawsuit against Pfizer/BioNTech over COVID vaccines
Reuters
Published Apr 04, 2023 08:17AM ET
Updated Apr 04, 2023 03:40PM ET
(Reuters) -Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc (NYSE:PFE) and its German partner BioNTech SE (NASDAQ:BNTX) in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents.
Arbutus, along with its licensee Genevant Sciences, is seeking damages, including reasonable royalties, over the use of lipid nanoparticle (LNP) delivery technology in Pfizer/BioNTech vaccines to carry and transfer genetic material into the body.
The lawsuit by Arbutus and Genevant says Pfizer/BioNTech engaged in licensing discussions for the technology but they did not "result in a settlement".
Genevant is a joint venture between Arbutus and Roivant Sciences Ltd.
Arbutus Biopharma (NASDAQ:ABUS) had also sued Moderna (NASDAQ:MRNA) Inc in the Delaware federal court last year, claiming the latter's mRNA COVID-19 vaccine also infringes its patents.
In its lawsuit against Moderna, Arbutus had said it was not looking to block the drugmaker from producing or distributing the vaccines but was seeking monetary damages including a reasonable royalty.
"Pfizer and BioNTech are aware that Arbutus Biopharma and Genevant Sciences have filed an action for infringement with respect to certain U.S. Patents," BioNTech told Reuters, and added that the companies would not comment on their legal strategy.
Pfizer had said earlier in the day that the company "will vigorously defend against the allegations of the lawsuit."
Arbutus declined to comment beyond the press release.
Moderna had sued Pfizer and BioNTech in August 2022 for allegedly infringing three patents related to their multibillion-dollar mRNA COVID-19 vaccines.
Pfizer and BioNtech are facing another patent infringement lawsuit related to the vaccines brought by Alnylam Pharmaceuticals Inc in March 2022.
Arbutus fell 2.6% to $2.98 on Tuesday, while Pfizer was down 1.2% and U.S.-listed shares of BioNtech dropped almost 3%.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.